Article

Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA.

The Cancer Registration Committee of the Japanese Urological Association, and Urology Division, National Cancer Center Hospital, Tokyo, Japan.
International Journal of Urology (Impact Factor: 1.73). 12/2011; 18(12):876-81. DOI: 10.1111/j.1442-2042.2011.02895.x
Source: PubMed

ABSTRACT In 2001, the Cancer Registration Committee of the Japanese Urological Association initiated a data collection of prostate cancer patients into a computer-based database. The aim of the present study is to report the clinical and pathological characteristics and outcomes of prostate cancer patients diagnosed in 2004 in Japan.
Overall, 11,385 patients from 239 institutions were registered into the database. After excluding 1105 patients because of insufficient data, duplication or insufficient follow up, 10,280 patients were eligible for the analysis. Most of them (10,198, 99.2%) were Japanese and 1195 (11.6%) had metastatic disease at the time of diagnosis. The mean and median follow up was 53.2 months and 61.5 months, respectively.
The 5-year overall and prostate cancer-specific survival rate was 89.7% and 94.8%, respectively. The 5-year prostate cancer-specific survival rate of M0 and M1 disease was 98.4% and 61.1%, respectively. For 8424 cases of organ-confined or regional disease, Japanese urologists used as the initial treatment hormone ablation therapy alone (3360, 39.9%), radical prostatectomy (3140, 38.1%), radiation therapy (1530, 18.2%) and watchful waiting (394, 4.7%) including active surveillance or palliative observation.
This is the first large population report of survival data in Japanese prostate cancer patients. In Japan, the disease population, survival period with metastatic disease and ratio of patients having hormone ablation therapy differ from those in Western countries.

0 Bookmarks
 · 
126 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We compared perioperative outcomes and costs between open and laparoscopic radical prostatectomy for prostate cancer. The Japanese Diagnosis Procedure Combination database, including cases from 2007 to 2010, was used by one-to-one propensity-score matching. The following items were compared: complication rate; homologous and autologous transfusion rate; first cystography day and cystography repeat rate; anesthesia time; postoperative length of stay; and costs. Multivariate analyses were carried out by including age, Charlson Comorbidity Index, T stage, hospital volume and hospital academic status as variables. As a result, among 15 616 open and 1997 laparoscopic radical prostatectomies, 1627 propensity-score matched pairs were generated. The laparoscopic approach showed a better overall complication rate (3.4% vs 5.0%), homologous transfusion rate (3.3% vs 9.2%), autologous transfusion rate (44.9% vs 79.3%), first cystography day (mean 6th vs 7th day), mean postoperative length of stay (mean 11 vs 13 days), and cost without surgery and anesthesia (mean $7965 vs $9235; all P < 0.001). Anesthesia time was longer (mean 345 vs 285 min) and total cost was higher (mean $14 980 vs $12 356) for the laparoscopic approach (both P < 0.001). The secondary cystography rates were comparable between the groups (18.3% vs 15.7%, P = 0.144). The multivariate analyses showed similar trends. In conclusion, these findings confirm several benefits of laparoscopy over open approach for radical prostatectomy.
    International Journal of Urology 01/2013; · 1.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The goals of the study were to examine surveillance biopsy and active treatment in patients under active surveillance (AS) for low-risk prostate cancer and to determine the active treatment-free survival rate. The subjects were 87 patients with low-risk prostate cancer who were under AS between 2000 and 2010. The eligibility criteria for AS were T1c, Gleason score ≤6, prostate-specific antigen level ≤10 ng/ml, one or two positive biopsies, maximum cancer involvement ≤50 %, and age ≤80 years old. Of the 87 patients, 48 underwent the first surveillance biopsy (55.2 %). In this biopsy, no cancer was found in 33.3 % of cases, 27.1 % remained eligible for AS, and 39.6 % did not meet the AS criteria (up-grade 22.9 %, up-volume 16.7 %). A second surveillance-biopsy was performed at 1.9 years after the first biopsy. No cancer was found in 20.0 % of cases, 40.0 % remained eligible for AS, and 40.0 % did not meet the AS criteria (up-grade 26.7 %, up-volume 13.3 %). A total of 50 patients received treatment by 1.7 years after starting AS, mainly due to an up-grade or up-volume. However, some patients underwent radiotherapy despite biopsy results indicating no cancer or eligibility for AS. The active treatment-free survival rate was 64.1 % after 2 years. Surveillance biopsy is important for identifying patients who require active treatment. The results in this study allowed determination of the active treatment-free survival rate and are informative for making treatment decisions.
    International Journal of Clinical Oncology 06/2013; · 1.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Little information on cancer coverage rather than newspaper and television is available. Japanese weekly magazines have a circulation of over 2,700,000 per week. To examine how they delivered urogenital cancer information to the public, cancer-related articles and advertisements in six major Japanese weekly magazines from 2009 to 2010 was ana-lyzed. 1.8% of total articles and advertisements were cancer-related. Prostate cancer (n = 119) was the second-most common topic, following lung cancer (n = 145), whereas only three articles were published on kidney or bladder cancer. The 53 articles on therapies for prostate cancer comprised radiotherapy (n = 29), surgery (n = 16), chemotherapy (n = 4), and others (n = 4). All 42 comments or interviews were cited in the article on prostate cancer, while 26 of them were attributed to only two famous doctors. Although cancer coverage in weekly magazines could be useful to spread infor- mation on prostate cancer, we should recognize their considerable bias based on a disproportionate emphasis.
    Open Journal of Urology 10/2013; 3(6):246-247.

Full-text (2 Sources)

View
2 Downloads
Available from
Oct 14, 2014